Methods for treatment of cardiovascular disease

• US 9,857,379 B2
• Filed: 10/24/2014
• Issued: 01/02/2018
• Est. Priority Date: 11/09/2000
• Status: Active Grant

• Current Assignee: Brigham and Women's Hospital Incorporated
• Original Assignee: Brigham and Women's Hospital Incorporated
• Inventors: Lee, Richard T.
• Primary Examiner(s): Landsman, Robert
• Assistant Examiner(s): Hissong, Bruce D
• Application Number:
  US14/523,694
• Publication Number:
  US 20150177259A1
• Time in Patent Office: 1,166 Days
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 2333/7155 for interleukins [IL]
• CPC Class Codes: G01N 2800/2871 Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
• CPC Class Codes: G01N 2800/32 Cardiovascular disorders
• CPC Class Codes: G01N 2800/323 Arteriosclerosis, Stenosis
• CPC Class Codes: G01N 2800/324 Coronary artery diseases, e.g. angina pectoris, myocardial infarction
• CPC Class Codes: G01N 2800/325 Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/5008 for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
• CPC Class Codes: G01N 33/5023 on expression patterns
• CPC Class Codes: G01N 33/5041 involving analysis of members of signalling pathways
• CPC Class Codes: G01N 33/5061 Muscle cells
• CPC Class Codes: G01N 33/5091 for testing the pathological state of an organism
• CPC Class Codes: G01N 33/6869 Interleukin
• CPC Class Codes: G01N 33/6887 from muscle, cartilage or connective tissue
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.

Claims

1. A method for identifying a subject as having a progressing cardiovascular condition and treating the subject, the method comprising:

(a) performing an immunoassay to determine a first level of soluble ST2 protein in a biological sample from a subject having a cardiovascular condition at a first time point, wherein the immunoassay comprises the use of a monoclonal antibody that binds specifically to soluble ST2 protein;

(b) comparing the first level of soluble ST2 protein to a predetermined value;

(c) identifying a subject having an elevated first level of soluble ST2 as compared to the predetermined level;

(d) performing an immunoassay(s) to determine a level of soluble ST2 protein in one or more additional biological samples from the identified subject over time, wherein the immunoassay(s) comprise(s) the use of a monoclonal antibody that binds specifically to soluble ST2 protein;

(e) identifying a subject having an elevated level(s) of soluble ST2 protein as determined in (d) as compared to the first level of soluble ST2 protein as having a progressing cardiovascular condition; and

(f) administering to a subject identified as having a progressing cardiovascular condition, an acute treatment for the progressing cardiovascular condition.

2. The method of claim 1, wherein the biological samples comprise a biological fluid.

3. The method of claim 2, wherein the biological fluid is blood or serum.

4. The method of claim 1, wherein the subject is human.

5. The method of claim 1, wherein the predetermined value is a level of soluble ST2 protein in a biological sample from a healthy subject.

6. The method of claim 1, wherein the acute treatment comprises a β

-adrenergic receptor blocker or a renin-angiotensin system inhibitor.

7. A method for identifying a subject as having a progressing myocardial infarction, stroke, or heart failure and treating the subject, the method comprising:

(a) performing an immunoassay to determine a first level of soluble ST2 protein in a biological sample from a subject having myocardial infarction, stroke, or heart failure at a first time point, wherein the immunoassay comprises the use of a monoclonal antibody that binds specifically to soluble ST2 protein;

(b) comparing the first level of soluble ST2 protein to a predetermined value;

(c) identifying a subject having an elevated first level of soluble ST2 protein as compared to the predetermined value;

(d) performing an immunoassay(s) to determine a level of soluble ST2 protein in one or more additional biological samples from the identified subject over time, wherein the immunoassay(s) comprise(s) the use of a monoclonal antibody that binds specifically to soluble ST2 protein;

(e) identifying a subject having an elevated level(s) of soluble ST2 protein as determined in (d) as compared to the first level of soluble ST2 protein as having a progressing myocardial infarction, stroke, or heart failure; and

(f) administering to a subject identified as having a progressing myocardial infarction, stroke, or heart failure, an acute treatment for the progressing myocardial infarction, stroke, or heart failure, respectively.

8. The method of claim 7, wherein the biological samples comprise a biological fluid.

9. The method of claim 8, wherein the biological fluid is blood or serum.

10. The method of claim 7, wherein the subject is human.

11. The method of claim 7, wherein the predetermined value is a level of soluble ST2 protein in a biological sample from a healthy subject.

12. The method of claim 7, wherein the subject has myocardial infarction.

13. The method of claim 7, wherein the subject has stroke.

14. The method of claim 7, wherein the subject has heart failure.

15. The method of claim 7, wherein the acute treatment comprises a β

-adrenergic receptor blocker or a renin-angiotensin system inhibitor.